DREAMM5
Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)
Arms / Cohorts
Comparator Arm:Belantamab Mafodotin
Accepting patients
Sub-study 1, Dose Expansion:Belantamab Mafodotin + GSK3174998
Accepting patients
Sub-study 2, Dose Expansion:Belantamab Mafodotin + Feladilimab
Accepting patients
Sub-study 3, Dose Expansion:Belantamab Mafodotin + Nirogacestat
Accepting patients
Sub-study 4, Dose Expansion:Belantamab Mafodotin + Dostarlimab
Accepting patients
Sub-study 5, Dose Expansion:Belantamab Mafodotin + Isatuximab
Accepting patients
Sub-study 6, Dose Expansion:Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone
Accepting patients
Sub-study 7, Dose Expansion:Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.